BBIO FY 2020 Earnings — BridgeBio Pharma, Inc. Revenue & Financial Results | Market Cap Arena

BBIOBridgeBio Pharma, Inc.

$14B

FY 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8M-79.7% YoY

Gross Profit

$8M100.0% margin

Operating Income

-$474M-5752.0% margin

Net Income

-$449M-5439.7% margin

EPS (Diluted)

$-4.10

Cash Flow

Operating Cash Flow

-$400M

Free Cash Flow

-$407M

Stock-Based Comp.

$58M

Balance Sheet

Total Assets

$704M

Total Liabilities

$596M

Stockholders' Equity

$58M

Cash & Equivalents

$356M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$41M	-79.7%
Gross Profit	$8M	$38M	-78.3%
Operating Income	-$474M	-$266M	-78.2%
Net Income	-$449M	-$260M	-72.3%